Dan Kemp is the founder of Wugen. Wugen has raised $200M in total funding. Latest round: Series B. Based in St. Louis, Missouri.
Daniel M. Kemp, Ph.D., is the Chief Executive Officer of Wugen Inc., a clinical-stage biotechnology company focused on developing allogeneic, off-the-shelf cell therapies for cancer. Under his leadership, Wugen has advanced its cell therapy platforms, including allogeneic memory NK and CAR-T cell therapies, into mid-stage clinical development. The company has raised over $200 million in venture funding, with a significant $172 million Series B round in July 2021. Dr. Kemp has a background in cell therapies and strategic business development, having previously held positions at Takeda Pharmaceuticals, Novartis, Merck, and Beryllium.
Full founder directory · Investor directory · Company funding database · Fundraising library